Levi & Korsinsky Reminds DexCom, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM

Core Viewpoint - DexCom, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 8, 2024, and July 25, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for DexCom investors following the company's announcement of its second-quarter financial results on July 25, 2024, which included a reduction in revenue guidance for the full fiscal year 2024 [2] - DexCom attributed its disappointing results and lowered guidance to the execution of "several key strategic initiatives" that "did not meet [their] high standards" [2] - Following the announcement, DexCom's stock price plummeted from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses in DexCom during the specified timeframe have until October 21, 2024, to request to be appointed as lead plaintiff in the lawsuit [2] - Participation in any potential recovery does not require serving as a lead plaintiff [2] Group 3: Legal Representation - Levi & Korsinsky, LLP, the firm representing the investors, has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3]